Brighton, UK-based infectious disease specialist Destiny Pharma (AIM: DEST) today announced that Chris Tovey will join the company as chief executive (CEO) on September 1, 2023.
Mr Tovey is taking over from Dr Debra Barker – interim CEO – who will return to her position as a non-executive director.
The company also announces the departure of its chairman, Nick Rodgers, who has resigned to pursue other interests. Discussions with a new outside chairman are very advanced with a further announcement expected shortly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze